X4 Pharmaceuticals Revenue and Competitors

The company is developing two unique programs: our drug candidate, X4P-001, has clinical experience in over 70 subjects and is advancing into Phase 1/2 trials in refractory clear cell renal cell carcinoma (ccRCC) and refractory epithelial ovarian cancer (EOC). Our second program, X4P-002, is a unique series of late lead molecules that penetrate the blood brain barrier. We will pursue early clinical development in glioblastoma multiforme (GBM), a rare form of lethal brain cancer, for the X4P-002 program. The target, CXCR4, plays a central role in tumor progression enabling cancer cells to establish a favorable microenvironment for growth, particularly in the setting of recurrence. Antagonism of the CXCR4 receptor has demonstrated an ability to inhibit the \"pro-tumor microenvironment\" by unmasking the tumor to the immune system, allowing it to recognize and destroy cancer cells and by eliminating the formation of the tumor blood supply. References: